PROPELLER Trial Results – SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer
Sydney, Australia 14 February 2023 Highlights PROPELLER trial achieved all primary and secondary objectives 64Cu SAR-bisPSMA was safe and well tolerated by trial participants Uptake of Clarity’s 64Cu SAR-bisPSMA in cancer lesions is higher compared to the approved standard-of-care for prostate cancer imaging in Australia and the US, 68Ga PSMA-11 Greater uptake into cancer lesions…